hERG SCREENING - An Exclusive Market Insight Report Update

The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data.

Hyderabad, India (prHWY.com) May 8, 2012 - April 18, 2012 - RI Technologies' ( http://www.researchimpact.com/ ) report on hERG Screening presents an in depth analysis of hERG Screening market. The study emphasizes on both technology and product segments of hERG Screening in biotechnology and pharmaceutical application areas. The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists more than 120 companies that are engaged in hERG Screening services and/or production of hERG screening tools/instruments. A global perspective is presented along with regional analysis covering North America, Europe, Asia-Pacific and Rest of World. Compilation of Worldwide Patents and Research related to hERG Screening is also provided. The market is analyzed in US Dollars and includes 33 exclusive graphically illustrated exhibits.

Human Ether-a-go-go Related Gene (hERG gene) (KCNH2) is an encoder of the potassium ion channel that repolarizes IKr current in the heart. It consists of 6 transmembrane domains which are serially numbered from S1-S6. The abnormalities resulting in this channel can either lead to Long QT syndrome (LQT2) or Short QTsyndrome causing loss of function mutations and gain of function mutations respectively. Both of these are considered as potentially fatal cardiac arrhythmia caused due to repolarisation disturbances of the cardiac action potential.

Global hERG Screening market is projected to grow at 28.97%, compounded annually from 2005 through 2015. hERG Screening has its major role in the pharmaceutical field in drug release process. Some drugs may prolong the QT interval in normal and healthy individuals and result in QT Syndrome. This side effect has promoted majority of pharmaceutical companies to screen compounds for hERG channel activity in early stages of drug discovery and development process. Many companies are developing cell lines such as HEK 293, and CHO to aid in vitro screening for hERG channel activity.

About RI Technologies

RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector with exclusive focus on product segments, global and regional market analysis, technology trends, industry outlook, competitor profiles, corporate directory and patents information. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The dedicated team works 24/7 to deliver unique reports that are of immense value to investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools. The company's reports provide strategic information tools to the manufacturers, retailers, distributors, and suppliers that will help them to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. The strategic market information tables, graphically represented, will aid companies' research needs and help in forecasting, and gearing up to the future. Emphasis is on factual insights and forecasts with maximum global coverage. The company strives to provide market insight reports that empower customers with enlightening critical business information.

###

Tag Words: herg screening

Categories: Research

Press Release Contact
Customer Support: contactus@researchimpact.com. Call us at INDIA: +91 9676994272 / UK: 076-24-057837 for your biotechnology and healthcare market research report requirements. We provide 24/7 online.

Link To This Press Release:

URL HTML Code